This inventor holds 191 USPTO granted patents and 31 published patent applications, plus 17 CIPO patents and 37 EPO patents, primarily in Antibody Therapeutics (CPC class C07K2317-24). Top assignees: Immunomedics, Inc., Eisai R&d Management Co., Ltd., Ibc Pharmaceuticals, Inc.. Active years: 1990-2021.
Inventors with similar research interests:
Location History:
- Flemington, NJ (US) (1990)
- Westfield, NJ (US) (1990 - 2002)
- Sidell, LA (US) (2004)
- Slidell, LA (US) (2002 - 2008)
- Morris Plains, NJ (US) (2002 - 2011)
- Mystic Island, NJ (US) (1994 - 2014)
- Picayune, MS (US) (2006 - 2019)
- Diamondhead, MS (US) (2017 - 2019)
- Somerville, MA (US) (2015 - 2021)
Company Filing History:
179 out of 410 
8 out of 530 
3 out of 72 
Years Active: 1990-2021
Areas of Expertise:
Title: Hans J Hansen: Pioneering Innovator in Cancer Research and Immunotherapy
Introduction:
Hans J Hansen, a renowned inventor in the field of cancer research and immunotherapy, has made significant contributions to advancements in cancer detection, diagnosis, and treatment. With an impressive track record of 177 patents, Hansen has focused on the isolation, detection, diagnosis, and characterization of circulating tumor cells (CTCs) and the development of combination therapies to induce immune responses against Trop-2 expressing tumors. This article will explore Hansen's latest patents, career highlights, collaborations, and his valuable contributions to the field of oncology.
Latest Patents:
Hansen's recent patents have focused on innovative approaches to combating Trop-2 positive cancers. One of his notable inventions includes the use of anti-Trop-2 antibodies or antigen-binding fragments to isolate, enrich, detect, diagnose, and characterize CTCs in patients with Trop-2 positive cancer. This method holds great promise for identifying and treating metastatic Trop-2 cancers, such as breast, ovarian, prostate, lung, colon, and other types of epithelial or head-and-neck cancer.
Additionally, Hansen's recent patents involve the development of bispecific antibodies that target both Trop-2 and CD3, inducing an immune response against Trop-2 expressing tumors. The bispecific antibodies can engage effector T cells, NK cells, monocytes, or neutrophils to enhance leukocyte-mediated cytotoxicity against Trop-2 cancer cells. These inventions offer a novel approach to immunotherapy, potentially revolutionizing the treatment of various cancers, including esophageal, pancreatic, stomach, bladder, breast, ovarian, uterine, kidney, and prostate carcinomas.
Career Highlights:
Hans J Hansen's career has been marked by his dedication to cancer research and immunotherapy. Having worked for prominent institutions and companies, he has played a pivotal role in advancing the field. Hansen's contributions at Immunomedics, Inc. have been instrumental in the development of innovative antibodies and therapeutic agents. Likewise, his tenure at The Ohio State University has allowed him to impart his knowledge and mentor future innovators.
Collaborations:
Throughout his career, Hans J Hansen has collaborated with distinguished professionals who share his passion for cancer research. Notably, he has worked closely with David M Goldenberg, a renowned researcher in cancer immunotherapy, and Zhengxing Qu, an accomplished scientist specializing in the development of innovative therapeutic approaches. These collaborations have fostered a synergistic environment that has resulted in numerous breakthroughs in the field. Hansen's partnerships have enriched his expertise and have contributed significantly to the advancement of cancer treatment modalities.
Conclusion:
Hans J Hansen has established his reputation as a pioneering innovator in the field of cancer research and immunotherapy. His relentless pursuit of novel approaches to cancer detection, diagnosis, and treatment has earned him an impressive portfolio of 177 patents. His recent patents, focusing on the isolation and characterization of circulating Trop-2-positive cancer cells and the development of combination therapies to induce immune responses, demonstrate his commitment to advancing the field's understanding and treatment of cancer. Hansen's collaborations with esteemed colleagues have further strengthened his contributions. Without a doubt, his groundbreaking work will continue to inspire and shape the future of cancer therapeutics.